Abivax reported first-quarter 2026 financial results, holding a cash position of €491.6 million that extends its runway into the fourth quarter of 2027. Research and development expenses rose to €49.5 million, driven by ongoing trials for new indications and Crohn's disease, while general and administrative costs declined due to lower personnel-related expenses. The company also released three-year interim data from its Study 108 trial of obefazimod in ulcerative colitis, showing that 68% of patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg once daily, with no new safety signals observed.
Abivax SACash runway extended through 2027 and positive interim data from ulcerative colitis trial.